Suraksha Diagnostic Ltd
Suraksha Diagnostic Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
Top 10 Healthcare Services companies on management guidance
See the sector's top 10 — free with your mobile number.
The short version
Q3 FY’26 revenue grew 30% YoY, driven by volume expansion and genomics product mix. Suraksha Diagnostic Limited expects strong topline momentum with 30% YoY revenue growth in Q3 FY’26 driven by volume expansion and product mix including genomics.
From Suraksha Diagnostic Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Q3 FY’26 revenue grew 30% YoY, driven by volume expansion and genomics product mix.
- Number of patients served increased by 23% YoY in Q3 FY’26.
- Number of tests performed grew 30.7% YoY in Q3 FY’26.
- Genomics segment showing strong growth: INR2.1-2.2 million monthly run rate and expected to scale further.
- Target to add 12-15 new centers annually, including six centers planned for Q4 FY’26 (3 big, 1 PPP, 2 small).
- Expansion into new geographies like Northeast India, Bihar, and Jharkhand is planned.
- Revenue per patient expected to grow with addition of high-value tests, especially genomics.
- No general price hikes expected, but incremental pricing on new tests planned.
2 more points from Suraksha Diagnostic Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Suraksha Diagnostic Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Suraksha Diagnostic Limited plans to open 12 to 15 new centers annually with a consistent capex of around INR 70 crores per year (Page 12).
- For FY’27, the company targets adding five large hub centers and 10 small centers with similar capex (~INR 70 crore) as prior years (Page 12).
- In Q4 FY’26, six centers are under development: three big centers, one PPP center, and two small centers; 60-70% expected operational in Q4 with possible spillover into next FY (Page 14).
2 more points from Suraksha Diagnostic Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Suraksha Diagnostic Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Suraksha Diagnostic Ltd said on order book & pipeline — free account, 30 seconds.
Suraksha Diagnostic Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹81 Cr, net profit ₹6 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Suraksha Diagno.'s management said in earlier quarters
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- Aster DM Quality Care LtdGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Suraksha Diagnostic Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Suraksha Diagnostic Ltd Q3 FY26 results?
Q3 FY’26 revenue grew 30% YoY, driven by volume expansion and genomics product mix. Suraksha Diagnostic Limited expects strong topline momentum with 30% YoY revenue growth in Q3 FY’26 driven by volume expansion and product mix including genomics.
What is Suraksha Diagnostic Ltd share price analysis?
Suraksha Diagnostic Ltd currently shows a neutral. The stock trades at a P/E of 44.4 with a market cap of ₹1,588 Cr. Investors should review the full earnings analysis for detailed insights.
Is Suraksha Diagnostic Ltd planning capital expenditure?
Suraksha Diagnostic Limited plans to open 12 to 15 new centers annually with a consistent capex of around INR 70 crores per year (Page 12).
Keep Suraksha Diagnostic Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.